CA2535451A1 - Method of treating viral infections - Google Patents

Method of treating viral infections Download PDF

Info

Publication number
CA2535451A1
CA2535451A1 CA002535451A CA2535451A CA2535451A1 CA 2535451 A1 CA2535451 A1 CA 2535451A1 CA 002535451 A CA002535451 A CA 002535451A CA 2535451 A CA2535451 A CA 2535451A CA 2535451 A1 CA2535451 A1 CA 2535451A1
Authority
CA
Canada
Prior art keywords
ribavirin
interferon
dose
day
slow
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002535451A
Other languages
English (en)
French (fr)
Inventor
Howard J. Smith
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Howard J Smith and Associates Pty Ltd
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34193246&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CA2535451(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Individual filed Critical Individual
Publication of CA2535451A1 publication Critical patent/CA2535451A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/7056—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/212—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
CA002535451A 2003-08-13 2004-08-03 Method of treating viral infections Abandoned CA2535451A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US49482803P 2003-08-13 2003-08-13
US60/494,828 2003-08-13
PCT/AU2004/001031 WO2005016370A1 (en) 2003-08-13 2004-08-03 Method of treating viral infections

Publications (1)

Publication Number Publication Date
CA2535451A1 true CA2535451A1 (en) 2005-02-24

Family

ID=34193246

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002535451A Abandoned CA2535451A1 (en) 2003-08-13 2004-08-03 Method of treating viral infections

Country Status (15)

Country Link
US (1) US20070202078A1 (https=)
EP (1) EP1660116A4 (https=)
JP (1) JP2007501806A (https=)
CN (1) CN1835765A (https=)
AR (1) AR045263A1 (https=)
AU (1) AU2004264255A1 (https=)
BR (1) BRPI0413474A (https=)
CA (1) CA2535451A1 (https=)
CL (1) CL2004002030A1 (https=)
IL (1) IL173630A0 (https=)
NO (1) NO20060651L (https=)
NZ (1) NZ545159A (https=)
RU (1) RU2371195C2 (https=)
WO (1) WO2005016370A1 (https=)
ZA (1) ZA200601181B (https=)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8101209B2 (en) 2001-10-09 2012-01-24 Flamel Technologies Microparticulate oral galenical form for the delayed and controlled release of pharmaceutical active principles
CA2480826C (fr) 2002-04-09 2012-02-07 Flamel Technologies Formulation pharmaceutique orale sous forme de suspension aqueuse de microcapsules permettant la liberation modifiee de principe(s) actif(s)
TW200510425A (en) * 2003-08-13 2005-03-16 Japan Tobacco Inc Nitrogen-containing fused ring compound and use thereof as HIV integrase inhibitor
CN1847256B (zh) * 2005-04-13 2011-06-15 长春华普生物技术有限公司 含CpG单链脱氧寡核苷酸和利巴韦林联合应用产生的抗病毒作用
WO2006131790A2 (en) * 2005-06-09 2006-12-14 Flamel Technologies Oral ribavirin pharmaceutical composition
WO2009031918A1 (ru) * 2007-09-05 2009-03-12 Shatunovsky Nikolai Evgenievic Композиции аполактоферрина и способы их применения в лечении вирусного гепатита с
WO2009046369A2 (en) * 2007-10-05 2009-04-09 Medtronic, Inc. Use of a specific dosage regimen of ifn-alpha and ribavirin for treating hepatitis c
PE20110343A1 (es) * 2008-09-17 2011-06-25 Boehringer Ingelheim Int Combinacion de inhibidor de la proteasa ns3 de hcv con interferon y ribavirina
US20110027229A1 (en) 2009-07-31 2011-02-03 Medtronic, Inc. Continuous subcutaneous administration of interferon-alpha to hepatitis c infected patients
EA201200650A1 (ru) 2009-10-30 2012-12-28 Бёрингер Ингельхайм Интернациональ Гмбх Курсы комбинированного лечения вируса гепатита с, включающие bi201335, интерферон-альфа и рибавирин
US20130295052A1 (en) 2010-11-19 2013-11-07 Manu Chaudhary Novel conjugates for targeted drug delivery
RU2665638C1 (ru) * 2017-05-24 2018-09-03 Общество С Ограниченной Ответственностью "Фарминтерпрайсез" Амидное соединение и его применение в качестве средства для лечения и профилактики заболеваний, вызываемых рнк-содержащими вирусами

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3222259A (en) * 1963-10-25 1965-12-07 Ethyl Corp Flare stack with a liquid seal
JPS5439143Y2 (https=) * 1976-04-16 1979-11-20
US6472373B1 (en) * 1997-09-21 2002-10-29 Schering Corporation Combination therapy for eradicating detectable HCV-RNA in antiviral treatment naive patients having chronic hepatitis C infection
DK1136075T3 (da) * 1997-09-21 2003-04-28 Schering Corp Kombinationsterapi til udryddelse aff detekterbart HCV-RNA i patienter med kronisk hepatitis C infektion
US6172046B1 (en) * 1997-09-21 2001-01-09 Schering Corporation Combination therapy for eradicating detectable HCV-RNA in patients having chronic Hepatitis C infection
CA2331823A1 (en) * 1998-05-15 1999-11-25 Schering Corporation Combination therapy comprising ribavirin and interferon alpha in antiviral treatment naive patients having g chronic hepatitis c infection
US6277830B1 (en) * 1998-10-16 2001-08-21 Schering Corporation 5′-amino acid esters of ribavirin and the use of same to treat hepatitis C with interferon
JP2002527522A (ja) * 1998-10-16 2002-08-27 シェリング・コーポレーション 慢性Ｃ型肝炎感染を有する患者における検出可能ＨＣＶ−ＲＮＡ根絶用リバビリン−インターフェロン−α併用療法
AR021876A1 (es) * 1998-12-18 2002-08-07 Schering Corp Terapia de combinacion para vhc por induccion de ribavirina - interferon alfa pegilado
US6962717B1 (en) * 1999-01-29 2005-11-08 Disphar International B.V. Pharmaceutical compositions
AU4463300A (en) * 1999-04-19 2000-11-02 Schering Corporation Hcv combination therapy, containing ribavirin in association with antioxidants
WO2001081359A1 (en) * 2000-04-20 2001-11-01 Schering Corporation Ribavirin-interferon alfa combination therapy for eradicating detectable hcv-rna in patients having chronic hepatitis c infection
EP1326594A2 (en) * 2000-10-18 2003-07-16 Schering Corporation Ribavirin-pegylated interferon alfa hcv combination therapy
US6544497B2 (en) * 2001-02-15 2003-04-08 Aeropharm Technology Incorporated Modulated release particles for aerosol delivery
PL369129A1 (en) * 2001-09-28 2005-04-18 Intermune, Inc. Method for treating hepatitis c virus infection in treatment failure patients
CA2372987A1 (en) * 2001-12-11 2003-06-11 Thomas R. Wiseman Method of disposal of liquid from gas wells

Also Published As

Publication number Publication date
RU2006107566A (ru) 2007-09-20
NZ545159A (en) 2009-03-31
AR045263A1 (es) 2005-10-19
JP2007501806A (ja) 2007-02-01
CN1835765A (zh) 2006-09-20
BRPI0413474A (pt) 2006-10-17
US20070202078A1 (en) 2007-08-30
RU2371195C2 (ru) 2009-10-27
IL173630A0 (en) 2006-07-05
CL2004002030A1 (es) 2005-06-03
WO2005016370A1 (en) 2005-02-24
EP1660116A4 (en) 2008-04-30
EP1660116A1 (en) 2006-05-31
ZA200601181B (en) 2007-04-25
NO20060651L (no) 2006-05-02
AU2004264255A1 (en) 2005-02-24

Similar Documents

Publication Publication Date Title
US20130109730A1 (en) Treatment of liver diseases in which iron plays a role in pathogenesis
EP1005868A1 (en) Use of alpha interferon and ribavirin in the manufacture of a medicament for combination therapy for chronic hepatitis C infection
KR20060120037A (ko) Ｈｃｖ 감염 치료용 병용 요법
US20070202078A1 (en) Method Of Treating Viral Infections
US20110165119A1 (en) Telaprevir dosing regimen
WO2012009503A1 (en) Palatable pharmaceutical composition comprising vx-950
JP2007501806A5 (https=)
US20150258167A1 (en) New Treatments of Hepatitis C Virus Infection
MXPA06001695A (en) Method of treating viral infections
KR20140011379A (ko) 알리스포리비르를 사용하는 c형 간염 바이러스 감염의 치료
TW201110976A (en) Medicinal agent and method for treatment of intractable chronic hepatitis c
NZ615539B2 (en) Treatment of hepatitis c virus infection with alisporivir

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued